Clinical research

DOI: 10.4244/EIJ-D-22-01037

Clinical outcomes of transcatheter mitral valve replacement: two-year results of the CHOICE-MI Registry

Sebastian Ludwig1,2,3, MD; Nils Perrin4, MD; Augustin Coisne3,5, MD, PhD; Walid Ben Ali4, MD, PhD; Jessica Weimann1, MSc; Alison Duncan6, MD; Mariama Akodad7, MD; Andrea Scotti3,8, MD;Daniel Kalbacher1,2, MD; Sabine Bleiziffer9, MD; Georg Nickenig10, MD; Jörg Hausleiter11, MD; Hendrik Ruge12,13, MD; Matti Adam14, MD; Anna S. Petronio15, MD; Nicolas Dumonteil16, MD; Lars Sondergaard17, MD; Marianna Adamo18, MD; Damiano Regazzoli19, MD; Andrea Garatti20, MD; Tobias Schmidt21, MD; Gry Dahle22, MD, PhD; Maurizio Taramasso23, MD; Thomas Walther24, MD; Joerg Kempfert25, MD; Jean-François Obadia26, MD; Omar Chehab27, MD; Gilbert H.L. Tang28, MD, MSc, MBA; Azeem Latib8, MD; Sachin Goel29, MD; Neil Fam30, MD; Martin Andreas31, MD, PhD; David W. Muller32, MD; Paolo Denti33, MD; Fabien Praz34, MD; Ralph Stephan von Bardeleben35, MD; Juan F. Granada3, MD; Thomas Modine36, MD, PhD; Lenard Conradi37*, MD; CHOICE-MI Investigators (collaborators)

Abstract

Background: Transcatheter mitral valve replacement (TMVR) using dedicated devices is an alternative therapy for high-risk patients with symptomatic mitral regurgitation (MR).

Aims: This study aimed to assess the 2-year outcomes and predictors of mortality in patients undergoing TMVR from the multicentre CHOICE-MI Registry.

Methods: The CHOICE-MI Registry included consecutive patients with symptomatic MR treated with 11 different dedicated TMVR devices at 31 international centres. The investigated endpoints included mortality and heart failure hospitalisation rates, procedural complications, residual MR, and functional status. Multivariable Cox regression analysis was applied to identify independent predictors of 2-year mortality.

Results: A total of 400 patients, median age 76 years (interquartile range [IQR] 71, 81), 59.5% male, EuroSCORE II 6.2% (IQR 3.8, 12.0), underwent TMVR. Technical success was achieved in 95.2% of patients. MR reduction to ≤1+ was observed in 95.2% at discharge with durable results at 1 and 2 years. New York Heart Association Functional Class had improved significantly at 1 and 2 years. All-cause mortality was 9.2% at 30 days, 27.9% at 1 year and 38.1% at 2 years after TMVR. Chronic obstructive pulmonary disease, reduced glomerular filtration rate, and...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 19 Number 6
Aug 21, 2023
Volume 19 Number 6
View full issue


Key metrics

On the same subject

10.4244/EIJV16I17A252 Apr 20, 2021
How to eliminate mitral regurgitation definitively: the eternal dilemma?
Modine T and Ben Ali W
free

Debate

10.4244/EIJ-E-22-00044 Mar 20, 2023
Transcatheter mitral valve replacement will remain a niche therapy: pros and cons
Cohen D et al
free

EXPERT REVIEW

10.4244/EIJ-D-18-00510 Sep 7, 2018
Patient selection for transcatheter mitral valve implantation: why is it so hard to find patients?
Urena M et al
free

State of the art

10.4244/EIJ-D-22-00890 Nov 17, 2023
Transcatheter mitral valve implantation for native valve disease
Urena M et al
free

10.4244/EIJV15I7A103 Sep 20, 2019
Mitral valve regurgitation: a plea for transcatheter mitral valve replacement
Modine T et al
free
Trending articles
159.48

State-of-the-Art

10.4244/EIJ-D-22-00725 Jan 23, 2023
Mitral valve transcatheter edge-to-edge repair
Hausleiter J et al
free
44.7

Image – Interventional flashlight

10.4244/EIJ-D-20-00325 Sep 20, 2021
A novel technique for percutaneous mitral balloon valvuloplasty
Aurigemma C et al
free
43

Clinical Research

10.4244/EIJ-D-21-01091 Aug 5, 2022
Lifetime management of patients with symptomatic severe aortic stenosis: a computed tomography simulation study
Medranda G et al
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2024 Europa Group - All rights reserved